INVESTORS & MEDIA
News Release
Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Understand AD: A Day in the Life Raises Awareness of Atopic Dermatitis by Sharing Real Stories from the
Today,
Moffat has suffered from severe AD for more than 50 years and was the first to portray to a broad audience what it's like to live with this debilitating disease through the popular
"I desperately wanted a global audience to get an intimate view of the burden caused by the intense, persistent itching and pain that someone living with this disease experiences every day," said
AD, the most common form of eczema, is a chronic, inflammatory skin disease characterized by unpredictable flare-ups driven in part by a malfunction in the immune system.[1]-[8] Despite common misconceptions that AD is "just" a skin condition, it is a systemic inflammatory disease that can have a significant physical and psychological impact on people.[7],[9] Some people with moderate-to-severe AD continue to experience debilitating symptoms despite available topical and systemic steroid treatment options, causing their disease to remain uncontrolled. This often unbearable disease can take control of people's lives, causing sleeplessness and feelings of anxiety, depression and isolation.[10]-[12]
"The Understand AD: A Day in the Life program signifies our commitment to driving education and growing public awareness of this serious and often overlooked disease," said
Visit www.UnderstandAD.com to view and share the "A Day in the Life" video, written and narrated by
About
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six
Regeneron is accelerating and improving the traditional drug development process through its unique VelociSuite® technologies and ambitious initiatives such as The Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
About
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
About
Contacts Regeneron:
Media Relations
Arleen Goldenberg
Tel: +1 (914) 847-3456
Mobile: +1 (914) 260-8788
Arleen.Goldenberg@regeneron.com
Contacts
Media Relations
Ashleigh Koss
Tel: +1 (908) 981-8745
ashleigh.koss@sanofi.com
Tel: +1 (908) 981-6486
Mobile: +1 (908) 247-6006
Carrie.Brown@sanofi.com
[1] Schneider et al, AAAI 2013, Practice Parameter Update, page 296.
[2] Eichenfield et al, AAD 2014, Guidelines of Care for Atopic Dermatitis, page 118.
[3] Guideline to treatment,
[4] Gelmetti and Wolleberg, BJD 2014, Atopic dermatitis- all you can do from the outside. Page 19.
[5]
[6] Gittler JK, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012; 130:6. 1345-1354.
[7] Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004; 113:651-657.
[8] Lebwohl MG, Del Rosso JQ, Abramovits W, et al. Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthet Dermatol. 2013; 6(7 Suppl):S2-S18.
[9] DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 2012; 33:227-34.
[10] Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their
partners. Dermatology. 2007; 215:123-129.
[11] Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006; 118:226-232.
[12] Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. Section 1. J Am Acad Dermatol. 2014;70:338-51.
SOURCE
News Provided by Acquire Media